Market Overview

GW Pharma Impresses Analysts With Phase 3 Trial Data

Share:
GW Pharma Impresses Analysts With Phase 3 Trial Data
Related GWPH
Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Over the weekend, GW Pharmaceuticals PLC – ADR (NASDAQ: GWPH) presented additional data from its Phase III trials of Epidiolex in Lennox-Gastaut (LGS) and Dravet syndromes, at the American Epilepsy Society (AES) meeting.

Cantor Fitzgerald’s Elemer Piros maintained a Buy rating on the company, with a price target of $182.

Phase III Data

Piros mentioned that “both studies achieved robust reductions of their primary endpoint in drop seizures and convulsive seizures, respectively.”

Responder analyses presented by GW Pharma at the AES meeting showed that Epidiolex was successful in achieving significant separations from the placebo group.

For Dravet, while responder analyses was marginally short of statistical significant, the analyst noted that “separation was maintained along the curves,” while the safety data demonstrated “a greater incidence of somnolence, diarrhea and decreased appetite in Dravet, compared with LGS.”

Piros believes that overall, the data highlighted Epidiolex’s significant ability to treat two orphan pediatric epilepsy indications, with distinct patient population characteristics.

The stock closed Friday's session at $112.32, up nearly 3 percent.

Latest Ratings for GWPH

DateFirmActionFromTo
Dec 2018OppenheimerInitiates Coverage OnPerform
Dec 2018Cantor FitzgeraldMaintainsOverweightOverweight
Nov 2018Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Elemer Piros EpidiolexAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (GWPH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DESPKeyBancInitiates Coverage On0.0
MELIKeyBancInitiates Coverage On0.0
ALBKeyBancMaintains120.0
AVNSKeyBancMaintains67.0
ABTCredit SuisseInitiates Coverage On82.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Lowe's Long-Term Goals To Become Less Aggressive

A Peek Into The Markets: U.S. Stock Futures Gain After Italian Vote Result